{"id":"NCT03180307","sponsor":"On Target Laboratories, LLC","briefTitle":"OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer","officialTitle":"A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-26","primaryCompletion":"2020-04-16","completion":"2020-10-16","firstPosted":"2017-06-08","resultsPosted":"2022-02-04","lastUpdate":"2022-02-04"},"enrollment":140,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Ovarian Cancer"],"interventions":[{"type":"DRUG","name":"OTL38","otherNames":["OTL38 for Injection"]},{"type":"DEVICE","name":"near infrared camera imaging system","otherNames":["Near IR imaging"]},{"type":"PROCEDURE","name":"laparotomy","otherNames":[]}],"arms":[{"label":"no fluorescent imaging","type":"SHAM_COMPARATOR"},{"label":"near infrared imaging arm","type":"EXPERIMENTAL"}],"summary":"This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery.","primaryOutcome":{"measure":"Efficacy Patient Level","timeFrame":"30 days","effectByArm":[{"arm":"Full Analysis Set","deltaMin":26.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":11,"countries":["United States","Netherlands"]},"refs":{"pmids":["36070540"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":150},"commonTop":["Nausea","Vomiting","Abdominal pain"]}}